NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Time-to-treatment-failure defined as progression after radiotherapy and one chemotherapy in either sequence
1999-2008
No
Michael Weller, MD
Principal Investigator
Department of Neurology, University of Zurich, Switzerland
Germany: Ethics Commission
NOA-04
NCT00717210
June 1999
March 2008
Name | Location |
---|